28 C
Vientiane
Saturday, May 3, 2025
spot_img
Home Blog Page 438

FiberHome Shines at MWC 2025: Pioneering a Bright Digital Future

BARCELONA, Spain, March 4, 2025 /PRNewswire/ — The global spotlight turned to the 2025 World Mobile Communications Congress (MWC), where FiberHome made a dazzling appearance under the theme “Connecting the Bright Digital Future.” Showcasing cutting-edge innovations across three key exhibition areas: Ultra-Efficient Infrastructure, AI-Driven Networks, and Unleash Digital Value, FiberHome demonstrated its leadership in driving the digital transformation of the information and communication industry.

Ultra-Efficiency Infrastructure: Redefining Connectivity

FiberHome unveiled its groundbreaking advancements in wireless communication, including high-efficiency antennas that leverage cutting-edge technologies like wireless/less-cable design, decoupling filters, and metamaterial boundaries. With over 150,000 4G/5G base stations deployed across 30+ countries, FiberHome is a global leader in 5G-A coverage, offering simplified solutions for cost-effective base station construction. FiberHome is also at the forefront of 6G research, with over 20,000 5G proposals and 21,000 patents, and has already achieved significant milestones in 6G development.

In the field of optical networks, FiberHome introduced its next-generation all-optical network architecture, featuring innovations like OTN P2MP for ultra-low latency and 100x bandwidth growth in access layer, and the industry’s highest-dimension 8×12 flexible scheduling network in metropolitan layer. The new COTP-F optical device, supporting single-wave rates up to 1.2T, sets a new benchmark for data center interconnectivity.

FiberHome showcases cutting-edge innovations in marine communication, 10G fiber access, and advanced optical fiber technologies. From island-to-island connectivity to transoceanic networks, the solutions redefine global communication. With 50G PON, Wi-Fi 7, and FTTR-B, FiberHome empowers homes and businesses with ultra-fast, seamless connectivity. Breakthroughs like 24-core fiber (5.29Pbit/s) and hollow-core fiber (270T capacity) set new standards for high-speed, high-capacity data transmission.

FiberHome is also leading the charge in green data center solutions, with innovative liquid cooling technologies that reduce PUE to below 1.1 and cut energy costs by 40%. These advancements not only support the growing demand for high-density computing but also align with global sustainability goals.

AI-Driven Networks: Intelligent Networks for a Smarter World

FiberHome’s AI-driven network solutions are revolutionizing the industry. By integrating AI with optical networks, FiberHome has achieved a 99% prediction accuracy rate, enhancing network resource utilization by 75% and improving operational efficiency by 30%. The AI-powered network operation services have already reduced failure rates by 52% and cut fault location time to mere minutes in overseas markets.

Unleash Digital Value: Empowering Industries

FiberHome’s smart solutions for industrial applications are equally impressive. The Smart Park solution, powered by the Fit-Access digital base and Fit-Sentry management platform, has improved operational efficiency by 15% in over 100 hospitals, hotels, schools, and industrial parks. In the transportation sector, FiberHome’s end-to-end smart traffic solutions, combining 5G private networks, AI algorithms, and big data analytics, are paving the way for a more efficient and sustainable modern transportation system.

As the digital era accelerates, FiberHome remains committed to innovation, collaboration, and sustainability, working hand-in-hand with global partners to create a faster, more stable, and intelligent digital world. Join us as we embark on this exciting journey towards a brighter digital future.

Contact us: marketing@fiberhome.com
Website: https://en.fiberhome.com


 


 

Ribbon Expands Portfolio of Innovative, Cost Efficient Routers

NPT 2714 and NPT 2705 deliver increased network flexibility and investment protection

TOKYO, March 4, 2025 /PRNewswire/ — Ribbon Communications Inc. (Nasdaq: RBBN), a prominent supplier of real-time communications technology and IP optical networking solutions, proudly announces the addition of two new routers to its NPT XDR2000 series: the NPT 2714, which has been recognized as a High Score Recipient in this year’s Lightwave + BTR Innovation Reviews, and the NPT 2507. Ribbon Is dedicated to assisting the world’s largest service providers, enterprises and critical infrastructure operators in modernizing and safeguarding their networks and services.

“These new routers are a testament to our continued focus on reducing the cost of networking, said Sam Bucci, Ribbon COO. “The advanced architecture of the 2714 enables the aggregation of increasing traffic volumes in a true pay as you go fashion, delivering superb performance and outstanding investment protection.”

NPT 2714

The NPT 2714 features a new, innovative, orthogonal architecture for modular centralized routers, merging the best aspects of modular and fixed systems. It combines the redundancy and I/O diversity of modular systems with the simplicity and cost-efficiency of fixed systems, which allows it to deliver redundancy at an optimized cost while enabling flexibility and expandability through operational continuity. 

Key features include:

  • True “Pay As You Grow”: offers the unique capability to start as a non-blocking 7.2Tbs switching capacity router and become a non-blocking 14.4Tbps router by adding 7.2Tbs switching card in-service.
  • Security: includes software-driven MACsec (Media Access Security), removing any hardware dependency and ensuring availability for all network interfaces
  • Coherent Routing (IPoDWDM): IP and DWDM on a single platform with 36 x 400G ZR+ coherent interfaces including plugin amplifiers to extend reach

NPT 2507

The NPT 2507 is a 7.2Tbps fixed form factor router which complements the NPT 2714 for a network solution where compact size for a fixed fan out of 100G and 400G interfaces are key requirements.

It supports:

  • High Capacity: 40 by 100G and 8 by 400G coherent interfaces.
  • Cost Efficiency: optimized for aggregating 100G traffic, meeting operational needs without unnecessary complexity.

These two platforms, which highlight Ribbon’s leadership in delivering innovative solutions that drive efficiency and performance for network operators worldwide, will be GA in Q3 2025.. For more information, please visit us in Booth 2C42 at Mobile World Congress.

About Ribbon
Ribbon Communications (Nasdaq: RBBN) delivers communications software, IP and optical networking solutions to service providers, enterprises and critical infrastructure sectors globally. We engage deeply with our customers, helping them modernize their networks for improved competitive positioning and business outcomes in today’s smart, always-on and data-hungry world. Our innovative, end-to-end solutions portfolio delivers unparalleled scale, performance, and agility, including core to edge software-centric solutions, cloud-native offers, leading-edge security and analytics tools, along with IP and optical networking solutions for 5G. We maintain a keen focus on our commitments to Environmental, Social and Governance (ESG) matters, offering an annual Sustainability Report to our stakeholders. To learn more about Ribbon, please visit rbbn.com.

Important Information Regarding Forward-Looking Statements 
The information in this release contains forward-looking statements regarding future events that involve risks and uncertainties. All statements other than statements of historical facts contained in this release, including those regarding the expected benefits from use of Ribbon Communication’s products, are forward-looking statements. The actual results of Ribbon Communications may differ materially from those contemplated by the forward-looking statements. For further information regarding risks and uncertainties associated with Ribbon Communications’ business, please refer to the “Risk Factors” section of Ribbon Communications’ most recent annual or quarterly report filed with the SEC. Any forward-looking statements represent Ribbon Communications’ views only as of the date on which such statement is made and should not be relied upon as representing Ribbon Communications’ views as of any subsequent date. While Ribbon Communications may elect to update forward-looking statements at some point, Ribbon Communications specifically disclaims any obligation to do so.

Investor Contact 
+1 (978) 614-8050
ir@rbbn.com       

Media Contact
Catherine Berthier
+1 (646) 741-1974
cberthier@rbbn.com 

Logo – https://laotiantimes.com/wp-content/uploads/2025/03/ribbon_logo.jpg 

Digital Domain and TOPPAN Holdings Launch Collaboration on Virtual Human Solutions

Utilizing biometric data from real-world people to create high-quality virtual humans that can be provided for diverse services

HONG KONG, March 4, 2025 /PRNewswire/ — Digital Domain Content (Hong Kong) Limited (“Digital Domain”), a wholly-owned subsidiary of Digital Domain Holdings Limited (stock code: 547), and TOPPAN Holdings Inc. (“TOPPAN Holdings”) have jointly announced the launch of a comprehensive collaboration this month. This follows the signing of a Memorandum of Understanding (MOU) to work together in the field of virtual humans, utilizing high-resolution data gathered from biometric scanning of real individuals.

The collaboration aims to create innovative solutions by integrating virtual humans developed from this high-precision biometric data into Digital Domain’s Momentum Cloud™.1 The biometric data is captured on a Light Stage2 at TOPPAN Holdings’ VIRTUAL HUMAN LAB™.3

Alleviating Labor Shortages and Accelerating Virtual Human Applications Development

Industries worldwide are facing labor shortages. According to a report by the McKinsey Global Institute, labor markets in advanced economies are among the tightest in two decades. Aging workforces have made this challenge a long-term trend, pushing companies and economies to explore new ways to expand labor capacity and boost productivity. Among the promising solutions is the development of AI technologies.

Technologies and applications related to virtual humans are evolving rapidly due to advancements in three-dimensional computer graphics and artificial intelligence. Virtual human technologies unrestricted by time or location, can flexibly meet the needs of global markets and are expected to be utilized in a range of fields, from entertainment to hospitality, retail, education, and healthcare, to enhance service experiences through creating innovative applications. Photorealistic virtual humans featured in corporate advertising and video content have garnered growing attention in recent years, and they are now being deployed for functions such as reception desks and facility guidance.

TOPPAN Holdings has been producing high-quality virtual humans based on biometric data captured on its Light Stage since 2020. The virtual humans created function as user interfaces for various services. Digital Domain, with over 30 years of experience in visual effects, AI virtual humans, and visualization, continues to develop cloud-based virtual human solutions through advanced production and cloud technologies.

By combining TOPPAN Holdings’ Light Stage scanning technologies and Digital Domain’s virtual human technologies, the collaboration aims to offer high-quality virtual human solutions to meet market demand and help alleviate labor shortages.

Mr. Hiroshi Asada, head of TOPPAN Holdings’ Business Innovation Center, stated, “TOPPAN has been promoting business development in the frontier field of virtual humans by using a Light Stage, a piece of cutting-edge human scanning technology. Digital Domain has a long track record of experience in the film industry for light stage production and also has a market-ready solution for the industry called Momentum Cloud™, so we expect significant synergy from this collaboration. We look forward to accelerating the market development of virtual humans and creating various use cases for each industry.”

Creating an Efficient Production Flow to Meet Market Demands

TOPPAN Holdings will conduct face scanning on a Light Stage, evaluate quality, develop business models for customized virtual humans, and provide original virtual human characters, while Digital Domain will import the high-resolution data obtained from the Light Stage into its Momentum Cloud™ platform to create and operate photorealistic virtual humans.

The collaboration will establish a high-quality, efficient production flow for virtual humans based on establishing production methods by utilizing AI and high-resolution data from face scanning on the Light Stage, enabling photorealistic virtual humans created from real-world people to be operated on Momentum Cloud™. This will reduce the lead time and cost for producing virtual humans, enabling a prompt and efficient response to requests for original character production.

Mr. William Wong, CEO of Digital Domain, stated, “Digital Domain is dedicated to developing AI-driven virtual human technologies, implementing applications, and creating sustainable business models for the future. As the significance of virtual humans increases across various industries, the pace of application development will also quicken. The virtual human solutions created in collaboration with TOPPAN Holdings will utilize both companies’ technological strengths to enhance virtual humans’ quality, performance, and effectiveness. These solutions will effectively meet market demands and create diverse application scenarios, opening up new opportunities for innovative business models.”

The collaboration aims to establish a production flow for virtual humans, which will help expand TOPPAN Holdings’ lineup of original virtual character offerings. This initiative will also provide solutions for casting these virtual humans for various services in the global market, utilizing Digital Domain’s Momentum Cloud™. By advancing pilot testing and business development that leverage the strengths of both companies, Digital Domain and TOPPAN Holdings aspire to create a virtual human solution business by the end of fiscal 2025.

1 Momentum Cloud™ is a server-based software platform for controlling virtual humans that can be used in the B2B2C space.

2 A Light Stage is a piece of equipment for high-precision face scanning developed by the University of Southern California.

3 The VIRTUAL HUMAN LAB™ was opened in December 2020 as a facility for advancing research and application development related to the use of face scanning and various other human biometric data.

About Digital Domain

Digital Domain is a pioneer in the virtualization of sensory experiences. After more than 3 decades of evolution, Digital Domain has transformed from a Hollywood company to achieve global expansion in fields such as VFX, AI virtual humans, and visualization. Digital Domain’s pursuit of creativity and advanced technologies has allowed the company to achieve unmatched refinement of its creative process as evidenced in the production of several hundred films and TV series as well as thousands of commercials, game graphics, and both experimental and immersive experiences. Digital Domain’s most outstanding achievements include: academy awards for “Best Visual Effects” in the films Titanic, What Dreams May Come, The Curious Case of Benjamin Button, blockbuster classics such as The Avengers series, and the 4th season of the popular word-of-mouth hit show Stranger Things.

As the first VFX studio that has achieved success in Greater China, Digital Domain entered the realm of virtual reality in 2016. By applying techniques such as fully integrating the base technology of AI and virtual reality, Digital Domain has constructed fully real-time photo-realistic digital characters capable of emotional expressivity. The extension of this technology outside of the silver screen provides a new medium for human-machine and human-human interactions in virtual scenarios.

Digital Domain is listed on the Hong Kong Stock Exchange (Stock code: 547) and is headquartered in Hong Kong and maintains operations in multiple cities including Los Angeles, Vancouver, Montreal, Beijing, Shanghai, Hyderabad, and more.

For more information, visit the official website – www.digitaldomain.com.

About the TOPPAN Group

Established in Tokyo in 1900, the TOPPAN Group is a leading and diversified global provider committed to delivering sustainable, integrated solutions in fields including printing, communications, security, packaging, décor materials, electronics, and digital transformation. The TOPPAN Group’s global team of more than 50,000 employees offers optimal solutions enabled by industry-leading expertise and technologies to address the diverse challenges of every business sector and society and contribute to the achievement of shared sustainability goals.

https://www.holdings.toppan.com/en/

https://www.linkedin.com/company/toppan/

Luang Prabang Declared Poverty-Free Amid Economic Growth

The ceremony of declaration Luang Prabang as a poverty-free Province (Photo: Lao National Radio)

On 3 March, Luang Prabang City was officially declared poverty-free, as announced by Mayor Viengthong Hatsachan. The declaration follows significant improvements in infrastructure and the economy, including better roads, transportation, and utilities.

Celltrion receives U.S. FDA approval for STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) biosimilars referencing PROLIA® and XGEVA®

  • STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of reference products PROLIA® (denosumab) and XGEVA® (denosumab) respectively[1], [2]
  • The FDA approval is based on robust clinical evidence, which show no clinically meaningful differences from the reference products
  • With the FDA approval of STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) Celltrion’s biosimilar portfolio continues to grow, expanding treatment options to reach more patients

JERSEY CITY, N.J., March 4, 2025 /PRNewswire/ — Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO® (CT-P41, denosumab-bmwo) and OSENVELT® (CT-P41, denosumab-bmwo), biosimilars referencing PROLIA® (denosumab) and XGEVA® (denosumab) respectively for all indications of reference products.[1], [2]

“The approval of STOBOCLO and OSENVELT is another step forward in our efforts to deliver cost-effective and high-quality treatments that address critical unmet needs in osteoporosis-related fracture as well as cancer-related skeletal events,” said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. “Patients deserve therapeutic options that have the potential to make real impacts on their care and their lives. We are committed to continuous innovation to meet these goals leveraging our experience and successful track record with biosimilar and novel biologics.”

The FDA approval is based on robust clinical evidence, including results from Phase III clinical trials in postmenopausal women with osteoporosis designed to evaluate the efficacy, pharmacodynamics (PD), pharmacokinetics (PK), safety and immunogenicity of CT-P41 to reference denosumab. Study results demonstrated that CT-P41 had equivalent efficacy and PD to reference denosumab with similar PK and comparable safety and immunogenicity profiles.

“Denosumab is used to improve or protect bone health in patients with osteoporosis or those undergoing various cancer treatments and as a therapy for a lifetime for postmenopausal osteoporosis (PMO) patients,” said Prof. Jean-Yves Reginster, Professor of Medicine, Protein Research Chair, Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia and Director WHO Collaborating Centre for Epidemiology of Musculoskeletal Health and Aging, Liège, Belgium. “Biosimilars have expanded into new therapeutic areas such as immunology, oncology and ophthalmology as they continue to offer significant cost-saving potential while expanding patient access. Having a denosumab product with a clinically proven track record in quality and safety is a valuable addition for my patients.”

In accordance with a settlement agreement with Amgen Inc., STOBOCLO and OSENVELT are expected to be available in the U.S. in June 2025.

About STOBOCLO® (denosumab-bmwo) 

STOBOCLO® (denosumab-bmwo) is a receptor activator of NF-κb ligand (RANKL) inhibitor referencing PROLIA® (denosumab). STOBOCLO 60 mg/mL injection is approved by the FDA based on comprehensive data and clinical evidence confirming the therapeutic equivalence to PROLIA. In the U.S., STOBOCLO is approved to treat postmenopausal women with osteoporosis at high risk for fracture, to increase bone mass in men with osteoporosis at high risk for fracture, to treat glucocorticoid-induced osteoporosis in men and women at high risk for fracture, to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. STOBOCLO was also approved by the European Medicines Agency (EMA) in February 2025.

INDICATIONS

STOBOCLO® (denosumab-bmwo) is a RANK ligand (RANKL) inhibitor indicated for treatment:

  • of postmenopausal women with osteoporosis at high risk for fracture
  • to increase bone mass in men with osteoporosis at high risk for fracture or in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
  • of glucocorticoid-induced osteoporosis in men and women at high risk for fracture
  • to increase bone mass in women at high risk for fracture receiving a adjuvant aromatase inhibitor therapy for breast cancer

IMPORTANT SAFETY INFORMATION

WARNING: SEVERE HYPOCALCEMIA IN PATIENTS WITH ADVANCED KIDNEY DISEASE

Patients with advanced chronic kidney disease, including those on dialysis, face a higher risk of severe hypocalcemia after denosumab administration, with reported cases leading to hospitalization, life-threatening events, and fatalities.

The presence of chronic kidney disease-mineral bone disorder (CKD-MBD) markedly increases the risk of hypocalcemia in these patients

Before starting STOBOCLO® (denosumab-bmwo) in advanced chronic kidney disease patients, assess for CKD-MBD. Treatment should be supervised by a healthcare provider experienced in diagnosing and managing CKD-MBD.

STOBOCLO is contraindicated in hypocalcemia, pregnant women, and in patients with known hypersensitivity to denosumab.

Severe Hypocalcemia: Ensure adequate calcium and vitamin D; monitor for severe hypocalcemia.

Drug Products with Same Active Ingredient: Do not use with other denosumab products.

Hypersensitivity: If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of STOBOCLO.

Osteonecrosis of the Jaw (ONJ): ONJ can occur in patients on STOBOCLO. Conduct oral exams before treatment; maintain oral hygiene; consider discontinuation of STOBOCLO if ONJ develops.

Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Monitor for thigh, hip, or groin pain; evaluate for fractures. Interruption of STOBOCLO therapy should be considered, pending a benefit-risk assessment, on an individual basis.

Multiple Vertebral Fractures (MVF) Following Discontinuation of Treatment: Increased risk post-discontinuation of denosumab; transition to alternative therapy if discontinuing STOBOCLO.

Serious Infections: Higher risk in denosumab users; assess benefit-risk profile, especially in immunocompromised patients. Assess the benefit-risk profile before starting STOBOCLO and reconsider its use if serious infections develop.

Dermatologic Adverse Reactions: Consider discontinuing STOBOCLO if severe dermatitis, eczema, or rashes occur.

Musculoskeletal Pain: Consider discontinuation of STOBOCLO if severe pain develops.

Bone Turnover Suppression: In clinical trials in women with postmenopausal osteoporosis, denosumab significantly suppressed bone remodelling; patients should be monitored for these outcomes.

Hypercalcemia in Pediatrics Patients with Osteogenesis Imperfecta: Not for pediatric use; hypercalcemia reported in patients osteogenesis imperfecta treated with denosumab products.

Most common Adverse Reactions:

  • In (>5%) of patients with: Postmenopausal osteoporosis were back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, and cystitis. Pancreatitis has been reported in clinical trials. Male osteoporosis were back pain, arthralgia, and nasopharyngitis.
  • Glucocorticoid-induced osteoporosis (> 3%) were back pain, hypertension, bronchitis, and headache.
  • Bone loss due to hormone ablation for cancer (≥ 10%) were arthralgia and back pain. Pain in extremity and musculoskeletal pain have also been reported in clinical trials.

For more information, see Full Prescribing Information.

About OSENVELT® (denosumab-bmwo) 

OSENVELT® (denosumab-bmwo) is a receptor activator of NF-κb ligand (RANKL) inhibitor referencing XGEVA® (denosumab). OSENVELT 120 mg/1.7 mL (70 mg/mL) injection is approved by the FDA based on a robust clinical trial and comprehensive data confirming the therapeutic equivalence to XGEVA. In the U.S., OSENVELT is indicated to prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors, to treat adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity, and to treat hypercalcemia of malignancy refractory to bisphosphonate therapy. OSENVELT was also approved by the European Medicines Agency (EMA) in February 2025.

INDICATION

OSENVELT® (denosumab-bmwo) is indicated for:

  • Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.
  • Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
  • Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

IMPORTANT SAFETY INFORMATION

Contraindications: Patients with hypocalcemia or with known clinically significant hypersensitivity to denosumab products.

Drug Products with Same Active Ingredient. Patients receiving OSENVELT should not receive other denosumab products concomitantly.

Hypersensitivity. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue further use of OSENVELT.

Hypocalcemia. Severe hypocalcemia can occur, and fatal cases have been reported. Monitor calcium levels and calcium and vitamin D intake.

Osteonecrosis of the Jaw (ONJ): ONJ can occur in patients on OSENVELT. Conduct oral exams and appropriate preventive dentistry before and during treatment; maintain oral hygiene and avoid invasive dental procedures; consider discontinuation of OSENVELT if ONJ develops.

Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Monitor for thigh, hip, or groin pain; evaluate for fractures. Interruption of OSENVELT therapy should be considered, pending a benefit-risk assessment, on an individual basis.

Hypercalcemia Following Treatment Discontinuation in Patients with Giant Cell Tumor of Bone and in Patients with Growing Skeletons. Clinically significant hypercalcemia, potentially requiring hospitalization, can occur within a year after stopping denosumab in patients with giant cell tumor of bone or growing skeletons; monitor serum calcium and manage calcium and vitamin D needs post-discontinuation.

Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation. Increased risk post-discontinuation of denosumab; evaluate for risk for vertebral fractures after discontinuing OSENVELT.

Embryo-Fetal Toxicity. Denosumab may cause fetal harm; verify pregnancy status before starting OSENVELT and advise effective contraception during treatment and for 5 months after the last dose.

Most common Adverse Reactions:

  • Bone Metastasis from Solid Tumors (≥ 25%) were fatigue/asthenia, hypophosphatemia, and nausea.
  • In patients (≥ 10%) with: Multiple Myeloma were diarrhea, nausea, anemia, back pain, thrombocytopenia, peripheral edema, hypocalcemia, upper respiratory tract infection, rash, and headache; Giant Cell Tumor of Bone were arthralgia, headache, nausea, back pain, fatigue, and pain in extremity.
  • Hypercalcemia of Malignancy (> 20%) were nausea, dyspnea, decreased appetite, headache, peripheral edema, vomiting, anemia, constipation, and diarrhea.

For more information, see Full Prescribing Information.

About Celltrion

Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us. and stay updated with our latest news and events on our social media – LinkedInInstagramX, and Facebook.

About Celltrion USA

Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion currently has seven biosimilars approved by the U.S. FDA: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), STEQEYMA® (Ustekinumab-stba), and AVTOZMA® (tocilizumab-anoh) as well as a novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion’s unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com, and stay updated with our latest news and events on our social media – LinkedIn

FORWARD-LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.

These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, “plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries’ management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect to the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company’s business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.

Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

Trademarks

STOBOCLO® and OSENVELT® are registered trademarks of Celltrion Inc.
PROLIA® and XGEVA® are registered trademarks of Amgen Inc.

References

[1] STOBOCLO U.S. prescribing information (2024)

[2] OSENVELT U.S. prescribing information (2024)

US-CT-P41-24-00010

For further information please contact: 
Andria Arena
aarena@jpa.com
+1 516-578-0057

Chulalongkorn University Unveils Exoskeleton Wheelchair to Aid Mobility

BANGKOK, March 4, 2025 /PRNewswire/ — Chulalongkorn University has introduced the Exoskeleton Wheelchair, an innovative robotic suit designed to help people with disabilities stand, walk, and move more independently. The breakthrough was developed by Assoc. Prof. Dr. Ronnapee Chaichaowarat from the Faculty of Engineering, aiming to improve mobility beyond traditional wheelchairs.

Chulalongkorn University Unveils Exoskeleton Wheelchair to Aid Mobility
Chulalongkorn University Unveils Exoskeleton Wheelchair to Aid Mobility

A New Frontier in Robotics

The robotics lab at Chulalongkorn University, located on the 9th floor of Chulapat-14 Building, serves as a hub for students and researchers from Thailand and abroad to collaborate on cutting-edge robotics projects. Dr. Ronnapee envisioned this lab as an alternative learning space, where students build and test robots through hands-on experimentation.

The World’s First Thai-Made Exoskeleton Wheelchair

Nicknamed “Thai Iron Man,” this innovation is the first exoskeleton wheelchair built by Thai researchers. Unlike conventional wheelchairs, it can transform to help users stand and walk, making it easier to navigate stairs or public transport. The project received funding from Thailand’s National Research Council (NRCT) in 2021–2022 and was a finalist in the 2024 Young Technologists Award.

How It Works

The Exoskeleton Wheelchair is a wearable robotic device that supports users by combining a wheelchair and exoskeleton into a hybrid system. Made with lightweight carbon fiber, and equipped with foldable wheels, the robot allows users to switch between sitting and walking modes with ease. A motorized system controls hip and knee joints, while the ankle joint remains flexible to ensure natural motion.

Engineering Meets Human Anatomy

Dr. Ronnapee integrated biomechanics and kinematics compatibility to create a device that mimics natural human movements. The exoskeleton must align with the user’s body to prevent discomfort or strain. A four-bar linkage system was implemented to enhance flexibility, ensuring the device moves in sync with human joints.

Challenges and Future Development

The prototype cost 130,000 baht and was funded by research grants. However, Assoc. Prof. Dr. Ronnapee believes Thailand’s aging population will drive demand for wearable robots. The team is currently developing a second prototype with improved stability for standing and walking. Clinical trials with patients are planned, pending Research Ethics Committee approval. If successful, this Thai-made exoskeleton wheelchair could revolutionize mobility assistance and position Thailand among global leaders in robotics.

For more information, contact ronnapee.c@chula.ac.th.

Read the full article at https://www.chula.ac.th/en/highlight/218151/

Media Contact:
Chula Communication Center
Email: Pataraporn.r@chula.ac.th

HKBU clinches four gold medals at the 15th International Invention Fair in the Middle East

HONG KONG, March 4, 2025 /PRNewswire/ — Hong Kong Baptist University (HKBU) won four gold medals at the 15th International Invention Fair in the Middle East (IIFME) held in Kuwait from 16 to 19 February. It was the first time that HKBU participated in the event.

Four HKBU inventions are awarded gold medals at the 15th International Invention Fair in the Middle East.
Four HKBU inventions are awarded gold medals at the 15th International Invention Fair in the Middle East.

Organised by the Kuwait Science Club under the patronage of His Highness, the Emir of Kuwait, IIFME is one of the largest specialised exhibitions of inventions and innovations in the Middle East. This year the event was organised in collaboration with the International Federation of Inventors’ Associations, the World Intellectual Property Organization, the United Nations Educational, Scientific and Cultural Organization, and the International Exhibition of Inventions of Geneva. The first IIFME was held in 2007 and this edition featured 180 inventors from 42 countries, showcasing a total of 230 inventions.

The four HKBU inventions that have secured gold medals are:

  • Lip-password-based Technology for Identity Verification project by Professor Cheung Yiu-ming, Chair Professor of the Department of Computer Science. The advanced changeable lip password provides secure identity verification based on lip motion, which can resolve the persistent problem of facial recognition in identical twins.
  • M-cell GP2-mediated Lymphatic-targeted Drug Carriers project by Professor Simon Han Quanbin, Professor of the Teaching and Research Division of the School of Chinese Medicine. The project applies a polysaccharide derived from the Chinese herbal medicine Mongolian Milkvetch Root to strengthen oral vaccine efficacy, offering a new treatment protocol for lymphatic diseases. 
  • Thermostable Pigment Nanofiber Coatings for Sustainable and Energy Saving Applications project by Professor Ken Leung Cham-fai, Associate Professor of the Department of Chemistry. This nanofiber technology enhances strength, durability, insulation, waterproofing, and corrosion resistance, reducing maintenance costs and extending structures’ lifespans. 
  • Hydrogen Production from Biomass Waste: Pioneering Advanced Technology for Sustainable Energy Solutions project by Professor Zhao Jun, Associate Professor of the Department of Biology. This technology converts biomass waste with catalysts to high yield green hydrogen in an efficient and environmentally friendly manner.

Aspiring to be a leading research-led university in Asia for the world, HKBU engages in cutting-edge, innovative and transdisciplinary research endeavours that push the boundaries of knowledge, address global issues, and contribute to the well-being of both local and international communities. HKBU’s award winning projects at this year’s IIFME exemplify the university’s unwavering dedication in translating research outcomes into practical applications for the benefit of mankind.

HKBN Survey Reveals Digital Transformation Progress Faced by Social Profit Organisations

80% of Respondents Report Insufficient Digitalisation;
Progress Stalled by Technology Knowledge and Funding Gaps

HONG KONG, March 4, 2025 /PRNewswire/ — Hong Kong Broadband Network Group (“HKBN”) has collaborated with The Social Investment Consultancy (TSIC) to conduct an in-depth survey on the digital transformation journey of ten large social profit organisations (“SPOs”). The survey aimed to identify the current state of digital adoption among SPOs, key challenges, and future needs.

This initiative underscores HKBN’s commitment to empowering the Hong Kong social welfare sector through technology – to enhance operational efficiency, elevate service quality, and remain resilient and responsive in an increasingly digital world.

The survey found that 80% of the SPOs rated their digitalisation at only 60% or below, indicating slow progress in digital transformation. A significant concern is the severe imbalance in IT support, with an average ratio of nearly one IT personnel for every 200 general staff. Furthermore, 60% of the SPOs cited insufficient technological skills among general staff, highlighting a critical shortage of IT talent and challenges in driving digital transformation.

Another major barrier to digital transformation is insufficient funding, with 80% of the SPOs reporting a lack of additional financial resources for digital initiatives. On the other hand, SPOs are eager to digitise administrative processes – such as financial workflows, approvals, and report preparation – to enhance efficiency and attract younger talent. Additionally, SPOs highlighted the need for upgrades to accounting and human resource management systems, including real-time dashboards, analytics, system integration, and e-rostering.

Sally Pang, Assistant Director of Hong Kong Christian Family Service Centre, stated, “SPOs need to manage vast amounts of data on members, volunteers, and event participants, as well as metrics such as service utilisation and event participation rates. Many SPOs aspire to leverage digital technology to optimise resource allocation, reduce administrative costs, and redirect their focus toward serving target audiences. Given that most donations are restricted for specific purposes, we urge the Government or charitable funds to provide more resources and support to help us keep pace with the business sector and achieve digital transformation.”

Jackal Chau, Senior Vice President – Solutions and Service Delivery, HKBN Enterprise Solutions, said, “HKBN Enterprise Solutions is dedicated to supporting SPOs to achieve comprehensive digital transformation through our enterprise resources and technological capabilities. We recognise that SPOs face challenges with staffing and resource constraints, which is why we recommend a phased approach to digitalisation. A practical starting point is financial systems, as most organisational data is ultimately tied to finance. Additionally, in this era of rapid development in artificial intelligence (AI), HKBN can provide a range of best-fit solutions to make AI accessible and affordable for the social welfare sector. By integrating these technologies into their operations, SPOs can significantly enhance efficiency, and streamline data management, allowing them to focus on expanding and improving their services for the communities.”

To promote digital inclusivity, HKBN established the HKBN SPO IT Club in 2023, offering voluntary services such as cybersecurity and IT training.

Interested SPOs can email esg@hkbn.com.hk to register for free consultation services and trial digital solutions. SPOs can also conduct a free online assessment to evaluate their digital readiness at https://bit.ly/hkbnes-digital-transformation.

About HKBN Ltd.

HKBN Ltd. (SEHK Stock Code: 1310, together with its subsidiaries, “HKBN”) is an investment holding company headquartered in Hong Kong, with operations in Hong Kong, Macau and mainland China.  As a leading integrated telecommunications and technology services provider, HKBN offers a comprehensive range of one-stop, high-quality information and communication technology (ICT) solutions, and an unlimited services portfolio. HKBN’s extensive tri-carrier fibre infrastructure covers around 2.6 million residential homes and 8,200 commercial buildings and facilities across Hong Kong.

Committed to creating a lasting positive impact wherever it operates, HKBN received the highest rating of AAA in the MSCI ESG Ratings in 2024. For more information about HKBN, please visit https://www.hkbn.net/group/en.